Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/648
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrown, Gregor-
dc.contributor.otherPellise, Maria-
dc.contributor.otherBurgess, Nicholas-
dc.contributor.otherTutticci, Nicholas-
dc.contributor.otherHourigan, Luke-
dc.contributor.otherZanati, Simon-
dc.contributor.otherSingh, Rajvinder-
dc.contributor.otherWilliams, Stephen-
dc.contributor.otherRaftopoulos, Spiro-
dc.contributor.otherOrmonde, Donald-
dc.contributor.otherMoss, Alan-
dc.contributor.otherByth, Karen-
dc.contributor.otherP'Ng, Heok-
dc.contributor.otherMahajan, Hema-
dc.contributor.otherMcLeod, Duncan-
dc.contributor.otherBourke, Michael-
dc.date2016-01-
dc.date.accessioned2016-05-11T03:57:33Z-
dc.date.available2016-05-11T03:57:33Z-
dc.date.issued2016-01-
dc.identifier.citationGut. 2016 Jan 19. pii: [Epub ahead of print]en_US
dc.identifier.issn1468-3288en_US
dc.identifier.urihttp://hdl.handle.net/11434/648-
dc.description.abstractOBJECTIVE: Endoscopic mucosal resection (EMR) is effective for large laterally spreading flat and sessile lesions (LSLs). Sessile serrated adenomas/polyps (SSA/Ps) are linked to the relative failure of colonoscopy to prevent proximal colorectal cancer. We aimed to examine the technical success, adverse events and recurrence following EMR for large SSA/Ps in comparison with large conventional adenomas. DESIGN: Over 74 months till August 2014, prospective multicentre data of LSLs ≥20 mm were analysed. A standardised dye-based conventional EMR technique followed by scheduled surveillance colonoscopy was used. RESULTS: From a total of 2000 lesions, 323 SSA/Ps in 246 patients and 1527 adenomas in 1425 patients were included for analysis. Technical success for EMR was superior in SSA/Ps compared with adenomas (99.1% vs 94.5%, p<0.001). Significant bleeding and perforation were similar in both cohorts. The cumulative recurrence rates for adenomas after 6, 12, 18 and 24 months were 16.1%, 20.4%, 23.4% and 28.4%, respectively. For SSA/Ps, they were 6.3% at 6 months and 7.0% from 12 months onwards (p<0.001). Following multivariable adjustment, the HR of recurrence for adenomas versus SSA/Ps was 1.7 (95% CI 0.9 to 3.0, p=0.097). Subgroup analysis by lesion size revealed an eightfold increased risk of recurrence for 20-25 mm adenomas versus SSA/Ps, but no significantly different risk between lesion types in larger lesion groups. CONCLUSION: Recurrence after EMR of 20-25 mm LSLs is significantly less frequent in SSA/Ps compared with adenomatous lesions. SSA/Ps can be more effectively removed than adenomatous LSLs with equivalent safety. Ensuring complete initial resection is imperative for avoiding recurrence. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT01368289.en_US
dc.publisherBritish Society of Gastroenterology, and BMJen_US
dc.subjectDepartment of Gastroenterology and Hepatology, Epworth HealthCare, Victoria, Australiaen_US
dc.subjectEndoscopic Mucosal Resectionen_US
dc.subjectEMRen_US
dc.subjectColonic Polypsen_US
dc.subjectColonoscopyen_US
dc.subjectColorectal Adenomasen_US
dc.subjectColorectal Canceren_US
dc.subjectEndoscopic Proceduresen_US
dc.subjectLaterally Spreading Flat and Sessile Lesionsen_US
dc.subjectLSLsen_US
dc.subjectSessile Serrated Adenomas/ Polypsen_US
dc.subjectSSA/Psen_US
dc.subjectLarge Conventional Adenomasen_US
dc.subjectGastroenterologyen_US
dc.titleEndoscopic mucosal resection for large serrated lesions in comparison with adenomas: a prospective multicentre study of 2000 lesions.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1136/gutjnl-2015-310249en_US
dc.identifier.journaltitleGuten_US
dc.description.pubmedurihttp://www.ncbi.nlm.nih.gov/pubmed/26786685en_US
dc.description.affiliatesDepartments of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia.en_US
dc.description.affiliatesWestmead Clinical School, University of Sydney, Sydney, New South Wales, Australia.en_US
dc.description.affiliatesDepartment of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.en_US
dc.description.affiliatesDepartment of Gastroenterology and Hepatology, Greenslopes Private Hospital, Brisbane, Queensland, Australia.en_US
dc.description.affiliatesDepartment of Gastroenterology and Hepatology, The Alfred Hospital, Melbourne, Victoria, Australiaen_US
dc.description.affiliatesDepartment of Gastroenterology and Hepatology, Western Hospital, Melbourne, Victoria, Australia.en_US
dc.description.affiliatesDepartment of Gastroenterology and Hepatology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.en_US
dc.description.affiliatesDepartment of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.en_US
dc.description.affiliatesNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.en_US
dc.description.affiliatesResearch and Education Network, Westmead Hospital, Sydney, New South Wales, Australia.en_US
dc.description.affiliatesInstitute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, New South Wales, Australia.en_US
dc.type.studyortrialMulticentre Studiesen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services
General Surgery and Gastroenterology

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.